122 related articles for article (PubMed ID: 3081722)
21. Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones as unique antihypertensive agents.
Press JB; Wright WB; Chan PS; Marsico JW; Haug MF; Tauber J; Tomcufcik AS
J Med Chem; 1986 May; 29(5):816-9. PubMed ID: 3517332
[TBL] [Abstract][Full Text] [Related]
22. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
[No Abstract] [Full Text] [Related]
23. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate.
Gorman RR; Johnson RA; Spilman CH; Aiken JW
Prostaglandins; 1983 Aug; 26(2):325-42. PubMed ID: 6316421
[TBL] [Abstract][Full Text] [Related]
24. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
25. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
26. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
27. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action.
Ushiyama S; Ito T; Asai F; Oshima T; Terada A; Matsuda K; Yamazaki M
Thromb Res; 1988 Sep; 51(5):507-20. PubMed ID: 3175990
[TBL] [Abstract][Full Text] [Related]
28. 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase.
Jacobs C; Frotscher M; Dannhardt G; Hartmann RW
J Med Chem; 2000 May; 43(9):1841-51. PubMed ID: 10794700
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of UK-38485 (dazmegrel), a specific inhibitor of thromboxane A2 synthetase.
Rebec MV; Skrinska VA
Prostaglandins Leukot Essent Fatty Acids; 1989 Dec; 38(3):207-12. PubMed ID: 2622975
[TBL] [Abstract][Full Text] [Related]
30. Thromboxane synthetase inhibitors and antihypertensive agents. 1. N-[(1H-imidazol-1-yl)alkyl]aryl amides and N-[(1H-1,2,4-triazol-1-yl)alkyl]aryl amides.
Wright WB; Press JB; Chan PS; Marsico JW; Haug MF; Lucas J; Tauber J; Tomcufcik AS
J Med Chem; 1986 Apr; 29(4):523-30. PubMed ID: 3959030
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion.
Menys VC; Davies JA
Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model.
Zheng NX; Sato H; Adachi I; Horikoshi I
Eur J Drug Metab Pharmacokinet; 1996; 21(4):285-93. PubMed ID: 9074892
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of prostacyclin and thromboxane A2 by rat gastric mucosa. Comparison of 1,6-dimethyl-4-oxo-1,6,7,8,9,9a-hexahydro-4H-pyrido (1,1-a)-pyrimidine-3-carboxamide and cimetidine.
Rózsa I; Kapui Z; Szécsi T; Hermecz I; Blaskó G
Arzneimittelforschung; 1989 Jun; 39(6):686-9. PubMed ID: 2673252
[TBL] [Abstract][Full Text] [Related]
34. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. IV. 2-[2-(1-Imidazolyl)ethyl]-4-(3-pyridyl)-1(2H)-phthalazinones.
Yamaguchi M; Koga T; Kamei K; Akima M; Maruyama N; Kuroki T; Hamana M; Ohi N
Chem Pharm Bull (Tokyo); 1994 Sep; 42(9):1850-3. PubMed ID: 7954937
[TBL] [Abstract][Full Text] [Related]
35. Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets.
Naito J; Komatsu H; Ujiie A; Hamano S; Kubota T; Tsuboshima M
Eur J Pharmacol; 1983 Jul; 91(1):41-8. PubMed ID: 6413227
[TBL] [Abstract][Full Text] [Related]
36. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
[TBL] [Abstract][Full Text] [Related]
37. The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.
Bunting S; Moncada S; Vane JR
Br Med Bull; 1983 Jul; 39(3):271-6. PubMed ID: 6354352
[No Abstract] [Full Text] [Related]
38. Thromboxane synthetase inhibition as antithrombotic strategy.
Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of thromboxane synthetase by the imidazole derivative 3-(1H-imidazol-1-yl-methyl)-2-methyl-1H-indole-1-propanoic acid as a novel therapeutic approach to experimental myocardial ischemia.
Korb H; Hoeft A; Wober W; Wolpers HG; Hellige G
Arzneimittelforschung; 1986 Jul; 36(7):1040-4. PubMed ID: 3768069
[TBL] [Abstract][Full Text] [Related]
40. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
